Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Richard J. Lin, Heidi D. Klepin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 59–62.

https://doi.org/10.1182/hematology.2019000076

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.

https://doi.org/10.1182/asheducation-2018.1.9

Published: 2018

Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.

https://doi.org/10.1182/asheducation-2017.1.317

Published: 2017

Journal Articles

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Marco Ruella, Pierre Soubeyran

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 432–436.

https://doi.org/10.1182/asheducation-2016.1.432

Published: 2016

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia

Daniel J. DeAngelo

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 400–405.

https://doi.org/10.1182/asheducation-2015.1.400

Published: 2015

Journal Articles

Chimeric antigen receptor T-cell therapy for ALL

Shannon L. Maude, Elizabeth J. Shpall, Stephan A. Grupp

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 559–564.

https://doi.org/10.1182/asheducation-2014.1.559

Published: 2014

Journal Articles

Does hematopoietic stem cell transplantation benefit infants with acute leukemia?

Edward Allan R. Sison, Patrick Brown

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 601–604.

https://doi.org/10.1182/asheducation-2013.1.601

Published: 2013

Journal Articles

Treatment of acute myeloid leukemia: are we making progress?

Alan K. Burnett

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 1–6.

https://doi.org/10.1182/asheducation.V2012.1.1.3797038

Published: 2012

Journal Articles

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Hillard M. Lazarus, Anjali S. Advani

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 382–388.

https://doi.org/10.1182/asheducation.V2012.1.382.3798359

Published: 2012

Journal Articles

Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?

Tanya Siddiqi, Didier Blaise

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 246–250.

https://doi.org/10.1182/asheducation.V2012.1.246.3806854

Published: 2012

Journal Articles

The prevalent predicament of relapsed acute myeloid leukemia

Jeffrey Szer

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 43–48.

https://doi.org/10.1182/asheducation.V2012.1.43.3798183

Published: 2012

Journal Articles

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Paolo Ghia

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 97–104.

https://doi.org/10.1182/asheducation.V2012.1.97.3798195

Published: 2012

Journal Articles

New Insights into Therapeutic Targets in Myeloma

Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 184–190.

https://doi.org/10.1182/asheducation-2011.1.184

Published: 2011

Journal Articles

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Emma Scott, Donna Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 205–207.

https://doi.org/10.1182/asheducation-2011.1.205

Published: 2011

Journal Articles

Treatment of Younger Patients with Chronic Lymphocytic Leukemia

Alessandra Ferrajoli

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 82–89.

https://doi.org/10.1182/asheducation-2010.1.82

Published: 2010

Journal Articles

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

Elihu Estey

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 474–480.

https://doi.org/10.1182/asheducation-2010.1.474

Published: 2010

Journal Articles

ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

Irene M. Ghobrial, A. Keith Stewart

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 587–589.

https://doi.org/10.1182/asheducation-2009.1.587

Published: 2009

NARROW

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Management of older Hodgkin lymphoma patients

Antibody-based therapies in patients with acute lymphoblastic leukemia

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

MRD in AML: does it already guide therapy decision-making?

The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia

Chimeric antigen receptor T-cell therapy for ALL

Does hematopoietic stem cell transplantation benefit infants with acute leukemia?

Treatment of acute myeloid leukemia: are we making progress?

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?

The prevalent predicament of relapsed acute myeloid leukemia

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

New Insights into Therapeutic Targets in Myeloma

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Treatment of Younger Patients with Chronic Lymphocytic Leukemia

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only